For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.

| Title | Content Type | Date | Description |
|---|---|---|---|
| Budesonide with eformoterol (Symbicort Turbuhaler) for asthma and chronic obstructive pulmonary disease | Professional publication - NPS RADAR - Brief item | 2011-12-01 00:00:00 | Budesonide with eformoterol (Symbicort Turbuhaler) is a fixed-dose combination product containing a long-acting bronchodilator (eformoterol) with a corticosteroid (budesonide). Budesonide with eformoterol is PBS listed for treatment of moderate to severe chronic obstructive pulmonary disease in people with frequent symptoms despite long-acting bronchodilator use and/or a history of recurrent exacerbations. |
| Montelukast (Singulair) PBS listed for exercise-induced asthma in children aged 6–14 years | Professional publication - NPS RADAR - Brief item | 2009-12-01 00:00:00 | The PBS listing for montelukast 5 mg tablets was extended on 1 December 2009 to include preventing exercise-induced asthma in children aged 6–14 years. |
| Budesonide with eformoterol dry powder inhaler (Symbicort) maintenance and reliever regimen for asthma | Professional publication - NPS RADAR - Review | 2007-08-01 00:00:00 | Reviews extended PBS listing for budesonide/eformoterol combination inhaler as an on-demand alternative to regular combination or corticosteroid therapy for asthma. |
| Ciclesonide (Alvesco) inhaler for asthma | Professional publication - NPS RADAR - Review | 2005-08-01 00:00:00 | Reviews use of ciclesonide inhaler for asthma, with emphasis on titration to minimum dose. |
| Montelukast (Singulair) in asthma | Professional publication - NPS RADAR - Review | 2003-01-01 00:00:00 | Reviews use of montelukast for frequent episodic or mild persistent asthma in children and adults as monotherapy or in combination with other antiasthmatic agents. |

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Date published: 2009-10-28 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.